Last reviewed · How we verify

Patients treated with Esketamine

Neuronetics · Phase 2 active Small molecule

Patients treated with Esketamine is a Small molecule drug developed by Neuronetics. It is currently in Phase 2 development. Also known as: spravato.

At a glance

Generic namePatients treated with Esketamine
Also known asspravato
SponsorNeuronetics
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Patients treated with Esketamine

What is Patients treated with Esketamine?

Patients treated with Esketamine is a Small molecule drug developed by Neuronetics.

Who makes Patients treated with Esketamine?

Patients treated with Esketamine is developed by Neuronetics (see full Neuronetics pipeline at /company/neuronetics).

Is Patients treated with Esketamine also known as anything else?

Patients treated with Esketamine is also known as spravato.

What development phase is Patients treated with Esketamine in?

Patients treated with Esketamine is in Phase 2.

Related